Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
With reference to the proposed EUDA-Theoremrx merger, the original LOI was signed on 4th October and announced on 5th October. The LOI provided for a 30 day exclusivity period with the option of a 15 day extension at the agreement of both parties. I believe that if it were 'working days' then surely it would have specified this
My interpretation is that the 30 day exclusivity period expired on 3rd November and we are now well into the extension period with the final date for a news release being 18th November. As the 18th November falls on a Saturday, I would expect news by close of business in the US Friday night
I recognize that the new project could be seen by some as creating a further strain on cash resources. One could also argue that having a 70% Innovate grant contribution being made towards the development of a potentially valuable asset - the precision dosing tool - is a good thing. The addition of G-CSF to the tool's capability could made it a much more attractive proposition for the likes of Dosemerx. I am happy with today's announcement
The swings in the share prices on AIM sometimes have to be taken with a large pinch of salt. Today we have had one-eighth of a per cent of the company issued share capital traded and we are supposedly 6.9% down
With regards to the fundraise, the PYC discount is not that unusual - it is the nature of the market at the moment
Light Science Technologies, were trading a 4p/share in April this year but could only raise funds at 1p/share. The low-price funding undermined shareholder confidence for the subsequent four months but is now looking much stronger and back trading close to 3p/share
What PYC is short of at the moment is news-flow. Once this happens I feel we could be in for a decent re-rate
In contrast to Valirx shareholders, EUDA shareholders appear unenthusiastic about a deal happening
Share price down from $1.55 immediately prior to the merger news on 4th October to $0.60 on pre-opening today
Recent Cromos Pharma article relating to Project Optimus :-
https://www.linkedin.com/pulse/enhancing-oncology-drug-dosage-optimization-project-optimus
Jim Millen has described Project Optimus as PYC's 'sweet spot'
The market reaction to the proposed merger between EUDA and Theoremrx has been interesting
THE EUDA share price on the day before the announcement was in the range $1.53-$1.55 and rallied following the announcement peaking at $1.93-$2.02 on 12th October. Since then it has fallen and is now in the range $0.80-$0.86
Is this a pointer as to whether the deal will go through. Time will tell. I see this as a 50%:50% call
Started investing here in Mark Chadwick days and been here almost continuously ever since. Sold out at c 4p when the big spike happened and bought back in some months later. Have just short of 1 million shares here
Have enjoyed observing the chat from the sidelines until recently
I suspect quite a number of PYC investors will have sold some or all of their holdings and moved into Valirx where positive news is anticipated, hence the drift in the PYC share price
The money will return if PYC can come up with some exciting news. I am looking forward to hearing news on the bio-statistics initiative
The Guardian article is quite relevant to the work PYC are involved in with regards to DNA damage and repair (DDR) and obtaining maximum benefit from existing drugs
PYC are involved with Merck on DNA-related work and in the RNS of 13th December 2021 Jim Millen comments ' In our view, there is no other company with Physiomics' experience in the field of DDR modelling and with every new project we further develop our capabilities in this field'
The PYC newsletter contained an article written by PYC employees/consultants with reference to personalised dosing, In it they comment 'While the quest for new drugs is of course essential, an alternative and much less expensive approach to improving outcomes is to use existing drugs more efficiently, concentrating on questions such as dosage and timing. There is increasing evidence that drugs can have a very different effect depending on the details of how and when they are taken, and on who they are taken by; and unlike the design of a radical new compound, such questions are often amenable to analysis using mathematical models.'